Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms

SIMPLE SUMMARY: Immune checkpoint inhibition has revolutionized clinical cancer care. As clinical use of these inhibitors increases, the ability to study the effects of these therapies in preclinical models becomes more important. This study highlights the need for using species appropriate reagents...

Descripción completa

Detalles Bibliográficos
Autores principales: Monjazeb, Arta M., Wang, Ziming, Vick, Logan V., Dunai, Cordelia, Minnar, Christine, Khuat, Lam T., Murphy, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916633/
https://www.ncbi.nlm.nih.gov/pubmed/33578798
http://dx.doi.org/10.3390/cancers13040729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916633/
https://www.ncbi.nlm.nih.gov/pubmed/33578798
http://dx.doi.org/10.3390/cancers13040729

Ejemplares similares